The Chief Executive of Eli Lilly has told the BBC that he is doubtful tariffs could bring manufacturing jobs to the US whilst ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

With two new lawsuits, Eli Lilly (NYSE: LLY) has escalated its legal campaign against the makers of unauthorized versions of ...

As the women’s NCAA March Madness tournament draws to a close, Eli Lilly is aiming for a slam dunk of its own. | As the women ...

Lilly’s recently-launched direct-to-consumer campaign also embraces a digital-first approach to reach eczema patients.

The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.

Eli Lilly (NYSE: LLY) is advancing its ambitions in cardiometabolic medicine with new mid-stage data showing that solbinsiran ...

Eli Lilly and Company is the world's most valuable Pharma thanks to tirzepatide, a groundbreaking GLP-1 weight-loss and Type 2 Diabetes drug, marketed and sold as Zepbound / Mounjaro. Hims & Hers ...

Eli Lilly (NYSE:LLY) shares dropped in price Wednesday, amid news the company is suing two pharmacies for compounding ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion on massive growth from its GLP-1 agonist products, Mounjaro for ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discusses. On Wednesday, Jim Cramer, the host of Mad Money ...